Drug Trial Radar · NCT03970733
Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis
Last checked: Nov 19, 2026Latest source record: Apr 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
246
Actual
Start
Jul 1, 2019
Primary completion
Apr 7, 2020
Study completion Mar 28, 2022
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Valneva Austria GmbH
- First posted
- May 31, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In the Main Study Phase a total of 246 subjects were randomized 2:2:1 into three treatment groups to receive either VLA15 with Alum (lower or higher dose) or Placebo. Main Study Phase vaccinations were administered as intramuscular injections on Day 1, Day 57 and Day 180. In the Booster Phase subjects from the higher dose group who completed their primary immunization schedule according to protocol will be randomized 2:1 to receive an additional higher dose VLA15 vaccination or Placebo at Month 18. Study duration in the Main Study Phase per subject is a maximum of 20 months. Overall study Duration is estimated to be 22 months. Study duration per subject in the Booster Phase is a maximum of approximately 13 months. Study duration per subject in the Main Study Phase and Booster Phase together is estimated to be a maximum of approximately 33 months. Overall study duration (i.e., First-Subject-In to Last-Subject Out/ end of Booster Phase) is estimated to be approximately 37 months.
Conditions
- Lyme Borreliosis
Interventions
VLA15Biological
a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
PlaceboBiological
PBS (Phosphate Buffered Saline)
Primary outcomes
What the sponsor says the trial is designed to measure.
- GMTs for IgG Against Each OspA SerotypeTime frame: Day 208 (Month 7)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Consulting, LLC
Milford, Connecticut
Stamford Therapeutics Consortium
Stamford, Connecticut
United Medical Associates
Binghamton, New York
Regional Clinical Research, Inc
Endwell, New York
Rochester Clinical Research, Inc.
Rochester, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.